There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BridgeBio Pharma (BBIO – Research Report) and ...

HC Wainwright reissued their buy rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a research report report published on Thursday,Benzinga reports. They currently have a $49.00 ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) is expected to issue its quarterly earnings data on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.82) per share and ...

Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $49 from $48 and keeps an Outperform rating on the ...

Shares of BridgeBio Pharma (NASDAQ:BBIO), currently valued at $5.88 billion, witnessed an uptick as Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target to $49 from $48 while ...

Scotiabank analyst Greg Harrison maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today and set a price target of $49.00.

The European Commission has granted marketing authorization in the European Union (EU) for acoramidis, under the brand name ...

RBC Capital Markets reiterated their positive stance on Alnylam Pharmaceuticals (NASDAQ:ALNY), maintaining an Outperform rating and a price target of $300.00. According to InvestingPro data, analyst ...

The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most ...